Objective:To develop habitat radiomics models to predict early treatment responses to the hepatic arterial infusion chemotherapy (HAIC) combined with targeted therapy or immunotherapy in advanced hepatocellular carcinoma (HCC) patients, and to guide clinical diagnosis and treatment.Methods:From October 2021 to Decemeber 2023, at Army Characteristic Medical Center of PLA (Chongqing Daping Hospital) and the First Affiliated Hospital of Chongqing Medical University, 94 patients with advanced HCC who received HAIC combined with targeted therapy or immunotherapy were retrospectively enrolled. According to the treatment results, the patients were divided into response group and non-response group. Univariate and multivariate logistic regression were performed to analyze the clinical data of the patients. Based on contrast-enhanced CT images, tumor habitats were delineated and habitat features were extracted with k-means clustering, and the imaging features of arterial and venous phases were also extracted. The least absolute shrinkage and selection operator (LASSO) was used for dimensionality reduction. Feature selection was performed using LASSO to reduce dimensions, and then the selected features were further refined through stepwise logistic regression analysis.Binary logistic regression models were conducted to develop the habitat radiomics model, arterial phase radiomics model (APRM), venous phase radiomics model (VPRM), clinical data model, as well as the combination of radiomics model and clinical data model to predict early treatment (after 2 treatment cycles) response. Receiver operating characteristic curves (ROC) were plotted, and model performance was evaluated by the area under the curve (AUC), calibration curves, and decision curve. The models were validated through Bootstrap methods (1 000 times). DeLong test was used to compare AUC values.Results:The results of cluster analysis identified 3 characteristic habitats in HCC imaging: low-, medium-, and high-enhancement tumor habitats. The proportion of high-enhancement habitats was higher than that in the non-response group. A predictive model was established based on the proportions of these 3 habitats. Based on the proportion of low-, medium-, and high-enhancement habitats within the tumor, a habitat radiomics model was constructed. After LASSO selection and logistic regression analysis, 3 arterial phase and 3 venous phase radiomic features were selected to build the APRM and VPRM, respectively. Logistic regression analysis identified the following factors for the clinical data model: comorbidities ( OR=0.275, P=0.031), maximum tumor diameter ( OR=1.149, P=0.019), red blood cell count ( OR=0.463, P=0.022), alpha fetoprotein >400 μg/L ( OR=3.452, P=0.017), and tyrosine kinase inhibitor therapy ( OR=3.072, P=0.048). Among the single predictive model′s comparison, the AUC of habitat radiomics model was 0.860 (95% confidence interval(95% CI): 0.789 to 0.932), while those of the APRM、VPRM and clinical data model were 0.850 (95% CI: 0.773 to 0.926), 0.855 (95% CI: 0.782 to 0.928), and 0.774 (95% CI: 0.681 to 0.867), respectively, and there were no statistically significant among these models (all P>0.05). Among the combination models, the AUC of the habitat rediomic-clinical data combination model was 0.881 (95% CI: 0.814 to 0.947); the AUC of arterial phase rediomic-clinical data combination model was 0.897 (95% CI: 0.833 to 0.961); and the AUC of venous phase rediomic-clinical data combination model was 0.888 (95% CI: 0.826 to 0.951), but there were no statistically significant among the 3 models (all P>0.05). The calibration curve showed that the habitat rediomic-clinical data combination model had the most accurate predictive probability. Internal validation showed that the AUC of habitat rediomic-clinical data combination model was 0.848 (95% CI: 0.772 to 0.922), and the predictive performance was better than that of the clinical-data model (0.733 (95% CI: 0.670 to 0.863)). Conclusion:The habitat radiomics model based on enhanced CT can effectively predict early treatment responses to the HAIC combined with targeted therapy or immunotherapy in advanced HCC patients, which provides theoretical basis for individualized treatment in advanced HCC.

Objective:To investigate the prognostic factors in patients with acute myocardial infarction (AMI) who underwent interventional therapy assisted by venous-arterial extracorporeal membrane oxygenation (VA-ECMO).Methods:This single-center retrospective cohort study enrolled AMI patients who received VA-ECMO-assisted interventional therapy in the Department of Cardiology at the Second Hospital of Jilin University from June 2018 to November 2022. Patients were divided into the in-hospital survival group and in-hospital death group based on the in-hospital survival. Data on patient demographics, laboratory tests, imaging examinations, coronary angiography results, VA-ECMO-related parameters, complications, and prognosis were collected through the electronic medical record system.Results:A total of 71 AMI patients were enrolled, with an age of (62.4±11.1) years, of whom 54 (76%) were male. There were 46 patients in the in-hospital survival group and 25 patients in the in-hospital death group. Compared to the in-hospital survival group, the in-hospital death group exhibited significantly higher levels of cardiac troponin I (36.08 (2.86, 100.00) μg/L vs. 2.75 (0.18, 13.86) μg/L, P=0.01) and B-type natriuretic peptide (1 724.50 (50.00, 4 200.50) vs. 460.85 (163.80, 1 862.33), P=0.01), and the left ventricular ejection fraction was lower ((35.0±12.9)% vs. (43.0±12.8)%, P=0.01), moreover the incidence of patients with left main coronary artery disease (80% (20/25) vs. 39% (18/46), P<0.01), cardiac arrest (56% (14/25) vs. 20% (9/46), P<0.01), cardiopulmonary resuscitation (52%(13/25) vs. 26%(12/46), P=0.03), and the time from cardiac arrest to ECMO initiation >24 hours (84% (21/25) vs. 9% (4/46), P<0.01) were higher. Conclusions:The prognosis of AMI patients undergoing VA-ECMO-assisted interventional therapy may be influenced by a number of related factors, including cardiac troponin I, B-type natriuretic peptide levels, left ventricular ejection fraction, combined with left main coronary artery disease, cardiac arrest and cardiopulmonary resuscitation, and the interval between cardiac arrest and the initiation of ECMO.

Objective:To explore the expression of growth differentiation factor-15 (GDF-15) in different pathological types of prostate cancer, and to analyze the impact of GDF-15 on biochemical recurrence of prostate cancer after radical prostatectomy.Methods:A retrospective analysis was conducted on the case data of 138 patients with prostate cancer who underwent radical prostatectomy at the 363rd Hospital from January 2019 to January 2022. The patients were divided into the recurrence group ( n=46) and the non-recurrence group ( n=92) based on postoperative biochemical recurrence. Measurement data were expressed as mean±standard deviation ( ± s), and analysis of variance was used for comparisons among multiple groups, while t-test was used for comparisons between two groups. Count data were expressed as the number of cases and percentages, and the Chi-test was used for comparisons between groups. Stratified regression analysis was used to explore the relationship between GDF-15 and different clinical pathological characteristics. By combining spline functions and Logistic regression analysis, the restricted cubic spline model was used to analyze the effect of GDF-15 on biochemical recurrence of prostate cancer in different pathological types. Kaplan-Meier survival curves were drawn to visually display the recurrence differences of prostate cancer patients at different GDF-15 levels. Results:The expression level of GDF-15 was the lowest in Gleason grade group (GGG)1 type at (548.71±78.25) pg/mL, and the highest in GGG5 type at (916.75±94.33) pg/mL, and the difference was statistically significant ( F=87.39, P<0.001). The level of GDF-15 was positively correlated with prostate-specific antigen (PSA), GGG5 type, and vascular endothelial growth factor (VEGF) ( P=0.029, 0.022, 0.015). The levels of PSA, GDF-15, Gleason score, alkaline phosphatase (ALP), C-reactive protein (CRP)/albumin (ALB), VEGF, and the proportion of TNM stage Ⅲ-Ⅳ, lymph node invasion, seminal vesicle invasion, nerve invasion, capsule rupture, and GGG5 type in the recurrence group were significantly higher than those in the non-recurrence group, the differences were all statistically significant ( P<0.05); the lymphocyte-to-monocyte ratio (LMR) was significantly lower than that in the non-recurrence group, and the difference was statistically significant ( P<0.001). GDF-15 had a non-linear dose-response relationship with the biochemical recurrence risk value. The risk value is significantly positively correlated with the level of GDF-15, and this relationship was not affected by the type of prostate cancer pathology. In patients with GGG1 to GGG5 types of prostate cancer, when the GDF-15 levels were >720, 700, 690, 650, and 610 pg/mL, respectively, the risk values increased as the GDF-15 levels rose. The Kaplan-Meier survival curve analysis showed that as the level of GDF-15 increased, the recurrence rate of patients significantly rose. Conclusions:The expression level of GDF-15 expression is the lowest in GGG1 type and the highest in GGG5 type. Both GDF-15 and GGG5 type are the independent risk factors for biochemical recurrence after radical prostatectomy, and GDF-15 exhibits a significant positive nonlinear dose-response relationship with the risk of biochemical recurrence.

Objective:To investigate the prognostic factors in patients with acute myocardial infarction (AMI) who underwent interventional therapy assisted by venous-arterial extracorporeal membrane oxygenation (VA-ECMO).Methods:This single-center retrospective cohort study enrolled AMI patients who received VA-ECMO-assisted interventional therapy in the Department of Cardiology at the Second Hospital of Jilin University from June 2018 to November 2022. Patients were divided into the in-hospital survival group and in-hospital death group based on the in-hospital survival. Data on patient demographics, laboratory tests, imaging examinations, coronary angiography results, VA-ECMO-related parameters, complications, and prognosis were collected through the electronic medical record system.Results:A total of 71 AMI patients were enrolled, with an age of (62.4±11.1) years, of whom 54 (76%) were male. There were 46 patients in the in-hospital survival group and 25 patients in the in-hospital death group. Compared to the in-hospital survival group, the in-hospital death group exhibited significantly higher levels of cardiac troponin I (36.08 (2.86, 100.00) μg/L vs. 2.75 (0.18, 13.86) μg/L, P=0.01) and B-type natriuretic peptide (1 724.50 (50.00, 4 200.50) vs. 460.85 (163.80, 1 862.33), P=0.01), and the left ventricular ejection fraction was lower ((35.0±12.9)% vs. (43.0±12.8)%, P=0.01), moreover the incidence of patients with left main coronary artery disease (80% (20/25) vs. 39% (18/46), P<0.01), cardiac arrest (56% (14/25) vs. 20% (9/46), P<0.01), cardiopulmonary resuscitation (52%(13/25) vs. 26%(12/46), P=0.03), and the time from cardiac arrest to ECMO initiation >24 hours (84% (21/25) vs. 9% (4/46), P<0.01) were higher. Conclusions:The prognosis of AMI patients undergoing VA-ECMO-assisted interventional therapy may be influenced by a number of related factors, including cardiac troponin I, B-type natriuretic peptide levels, left ventricular ejection fraction, combined with left main coronary artery disease, cardiac arrest and cardiopulmonary resuscitation, and the interval between cardiac arrest and the initiation of ECMO.

Objective:To develop habitat radiomics models to predict early treatment responses to the hepatic arterial infusion chemotherapy (HAIC) combined with targeted therapy or immunotherapy in advanced hepatocellular carcinoma (HCC) patients, and to guide clinical diagnosis and treatment.Methods:From October 2021 to Decemeber 2023, at Army Characteristic Medical Center of PLA (Chongqing Daping Hospital) and the First Affiliated Hospital of Chongqing Medical University, 94 patients with advanced HCC who received HAIC combined with targeted therapy or immunotherapy were retrospectively enrolled. According to the treatment results, the patients were divided into response group and non-response group. Univariate and multivariate logistic regression were performed to analyze the clinical data of the patients. Based on contrast-enhanced CT images, tumor habitats were delineated and habitat features were extracted with k-means clustering, and the imaging features of arterial and venous phases were also extracted. The least absolute shrinkage and selection operator (LASSO) was used for dimensionality reduction. Feature selection was performed using LASSO to reduce dimensions, and then the selected features were further refined through stepwise logistic regression analysis.Binary logistic regression models were conducted to develop the habitat radiomics model, arterial phase radiomics model (APRM), venous phase radiomics model (VPRM), clinical data model, as well as the combination of radiomics model and clinical data model to predict early treatment (after 2 treatment cycles) response. Receiver operating characteristic curves (ROC) were plotted, and model performance was evaluated by the area under the curve (AUC), calibration curves, and decision curve. The models were validated through Bootstrap methods (1 000 times). DeLong test was used to compare AUC values.Results:The results of cluster analysis identified 3 characteristic habitats in HCC imaging: low-, medium-, and high-enhancement tumor habitats. The proportion of high-enhancement habitats was higher than that in the non-response group. A predictive model was established based on the proportions of these 3 habitats. Based on the proportion of low-, medium-, and high-enhancement habitats within the tumor, a habitat radiomics model was constructed. After LASSO selection and logistic regression analysis, 3 arterial phase and 3 venous phase radiomic features were selected to build the APRM and VPRM, respectively. Logistic regression analysis identified the following factors for the clinical data model: comorbidities ( OR=0.275, P=0.031), maximum tumor diameter ( OR=1.149, P=0.019), red blood cell count ( OR=0.463, P=0.022), alpha fetoprotein >400 μg/L ( OR=3.452, P=0.017), and tyrosine kinase inhibitor therapy ( OR=3.072, P=0.048). Among the single predictive model′s comparison, the AUC of habitat radiomics model was 0.860 (95% confidence interval(95% CI): 0.789 to 0.932), while those of the APRM、VPRM and clinical data model were 0.850 (95% CI: 0.773 to 0.926), 0.855 (95% CI: 0.782 to 0.928), and 0.774 (95% CI: 0.681 to 0.867), respectively, and there were no statistically significant among these models (all P>0.05). Among the combination models, the AUC of the habitat rediomic-clinical data combination model was 0.881 (95% CI: 0.814 to 0.947); the AUC of arterial phase rediomic-clinical data combination model was 0.897 (95% CI: 0.833 to 0.961); and the AUC of venous phase rediomic-clinical data combination model was 0.888 (95% CI: 0.826 to 0.951), but there were no statistically significant among the 3 models (all P>0.05). The calibration curve showed that the habitat rediomic-clinical data combination model had the most accurate predictive probability. Internal validation showed that the AUC of habitat rediomic-clinical data combination model was 0.848 (95% CI: 0.772 to 0.922), and the predictive performance was better than that of the clinical-data model (0.733 (95% CI: 0.670 to 0.863)). Conclusion:The habitat radiomics model based on enhanced CT can effectively predict early treatment responses to the HAIC combined with targeted therapy or immunotherapy in advanced HCC patients, which provides theoretical basis for individualized treatment in advanced HCC.

Objective The aim of this study was to analyze the incidence and mortality of lung cancer in tumor registration areas of Yunnan province in 2020,as well as the changing trends from 2012 to 2020,in order to provide the data support for lung cancer prevention and control.Methods The reported cases of lung cancer from 2012 to 2020 in tumor registration areas of Yunnan province were collected,and SAS 9.4 software was used to calculate the incidence,mortality and other indicators to describe the cur-rent situation of lung cancer incidence and mortality.JoinPoint 4.9.0.0 software was used to calculate the annual percentage change(APC)to analyze the trend of lung cancer incidence and mortality.Results In 2020,the crude incidence of lung cancer in Yunnan province was 46.68/100,000(male 58.56/100,000 and female 34.21/100,000),age-standardized incidence rate by Chinese stand-ard population(ASIRC)was 30.83/100,000,age-standardized incidence rate by World standard population(ASIRW)was 30.61/100,000;The crude mortality was 33.88/100,000(male 45.94/100,000 and female 21.21/100,000),age-standardized mortality rate by Chinese standard population(ASMRC)was 21.70/100,000,age-standardized mortality rate by World standard population(ASMRW)was 21.61/100,000.In 2020,the incidence and mortality of lung cancer in Yunnan province showed an upward trend with the increase of age,and was at a low level before the age of 39,and increased rapidly after the age of 40.It reached its peak in the age groups of 75-79 and 80-84,respectively.The crude incidence of lung cancer in urban and rural areas was 47.21/100,000 and 46.52/100,000,respectively;The crude mortality of lung cancer was 32.66/100,000 and 34.27/100,000,respectively.From 2012 to 2020,the crude incidence of lung cancer in Yunnan province increased with the year(APC=2.94%,95%CI=0.29%-5.67%,P<0.05);The crude incidence of female lung cancer and ASIRW increased with the year(crude incidence rate:APC=6.30%,95%CI=2.52%-10.21%,P<0.05;ASIRW:APC=5.91%,95%CI=1.21%-10.82%,P<0.05).Conclusion In 2020,the incidence and mortality of lung cancer in Yunnan province increase significantly after the age of 40.The overall incidence and mortality of lung cancer in men are higher than those in women,and higher in rural areas than that in urban areas.At the same time,the incidence of lung cancer in women is increasing year by year.Therefore,males 40 years old and over above in rural areas should be identified as key populations for lung cancer prevention and control.Simultaneously,women lung cancer also pay attention to the prevention and control.

Background::Histological healing is closely associated with improved long-term clinical outcomes and lowered relapses in patients with ulcerative colitis (UC). Here, we developed a novel diagnostic criterion for assessing histological healing in UC patients.Methods::We conducted a retrospective cohort study in UC patients, whose treatment was iteratively optimized to achieve mucosal healing at Shanghai Tenth People’s Hospital of Tongji University from January 2017 to May 2022. We identified an inflammatory cell enumeration index (ICEI) for assessing histological healing based on the proportions of eosinophils, CD177 + neutrophils, and CD40L + T cells in the colonic lamina propria under high power field (HPF), and the outcomes (risks of symptomatic relapses) of achieving histological remission vs. persistent histological inflammation using Kaplan-Meier curves. Intrareader reliability and inter-reader reliability were evaluated by each reader. The relationships to the changes in the Nancy index and the Geboes score were also assessed for responsiveness. The ICEI was further validated in a new cohort of UC patients from other nine university hospitals. Results::We developed an ICEI for clinical diagnosis of histological healing, i.e., Y = 1.701X 1 + 0.758X 2 + 1.347X 3 - 7.745 (X 1, X 2, and X 3 represent the proportions of CD177 + neutrophils, eosinophils, and CD40L + T cells, respectively, in the colonic lamina propria under HPF). The receiver operating characteristics curve (ROC) analysis revealed that Y <-0.391 was the cutoff value for the diagnosis of histological healing and that an area under the curve (AUC) was 0.942 (95% confidence interval [CI]: 0.905-0.979) with a sensitivity of 92.5% and a specificity of 83.6% ( P <0.001). The intraclass correlation coefficient (ICC) for the intrareader reliability was 0.855 (95% CI: 0.781-0.909), and ICEI had good inter-reader reliability of 0.832 (95% CI: 0.748-0.894). During an 18-month follow-up, patients with histological healing had a substantially better outcome compared with those with unachieved histological healing ( P <0.001) using ICEI. During a 12-month follow-up from other nine hospitals, patients with histological healing also had a lower risk of relapse than patients with unachieved histological healing. Conclusions::ICEI can be used to predict histological healing and identify patients with a risk of relapse 12 months and 18 months after clinical therapy. Therefore, ICEI provides a promising, simplified approach to monitor histological healing and to predict the prognosis of UC.Registration::Chinese Clinical Trial Registry, No. ChiCTR2300077792.

BACKGROUND:Spheroid culture of mesenchymal stem cells in bioreactors is an in vitro culture method to maintain their stemness properties and allow for large-scale expansion.Clarifying its effects on the immunoregulation effect of stem cells is beneficial for their clinical application. OBJECTIVE:To investigate the effects of spheroid culture in a rotating bioreactor on the secretion of inflammatory factors by human placenta-derived mesenchymal stem cells. METHODS:Placenta-derived mesenchymal stem cells isolated from human placenta tissue were cultured in two-dimensional culture or a rotating bioreactor culture.Cell morphology and proliferation ability were observed using inverted phase contrast microscopy,immunohistochemical staining,and CCK-8 assay.The gene expression and protein secretion of several inflammatory factors were detected by RT-qPCR and flow immunofluorescence assay. RESULTS AND CONCLUSION:(1)Mesenchymal stem cells cultured in a rotating bioreactor aggregated into multicellular spheroids,which gradually increased in number and volume.(2)The hematoxylin-eosin staining results showed that the mesenchymal stem cells cultured in the rotating bioreactor for 4 days were evenly distributed and had normal morphology in the spheroids.(3)Immunohistochemical staining results revealed many mesenchymal stem cells with Ki-67 positive in the spheroids.(4)The CCK-8 assay results exhibited that the viability of mesenchymal stem cells derived from spheroid culture was significantly higher than that of cells cultured in two-dimensional culture.(5)The results of RT-qPCR and flow immunofluorescence assay demonstrated that the gene expression and protein secretion(interleukin 1β,interleukin-4,interleukin-6,interleukin-8,interleukin-10,interleukin-17,tumor necrosis factor α and interferon α)of inflammatory factors derived from mesenchymal stem cells cultured in the rotating bioreactor were significantly higher than those in two-dimensional culture.(6)Our results indicate that spheroid culture in a rotating bioreactor can significantly elevate the secretion ability of various inflammatory factors by human placenta-derived mesenchymal stem cells,and enhance the immunoregulatory effect of human placenta-derived mesenchymal stem cells.

The ultrasonic manifestations of benign and malignant breast imaging-reporting and data system(BI-RADS)4 lesions overlap in some degrees,is able to result in unnecessary biopsy or untimely therapy.Accurate classifying the nature of BI-RADS 4 breast lesions can provide reliable references for clinical decision-making.The progresses of application of new ultrasonic technologies,including automated breast volume scanner,superb micro-vascular imaging,elastography,contrast-enhanced ultrasound and artificial intelligence for assisting diagnosis of BI-RADS 4 lesions were reviewed in this article.

Objective The aim of this study was to analyze the incidence and mortality of lung cancer in tumor registration areas of Yunnan province in 2020,as well as the changing trends from 2012 to 2020,in order to provide the data support for lung cancer prevention and control.Methods The reported cases of lung cancer from 2012 to 2020 in tumor registration areas of Yunnan province were collected,and SAS 9.4 software was used to calculate the incidence,mortality and other indicators to describe the cur-rent situation of lung cancer incidence and mortality.JoinPoint 4.9.0.0 software was used to calculate the annual percentage change(APC)to analyze the trend of lung cancer incidence and mortality.Results In 2020,the crude incidence of lung cancer in Yunnan province was 46.68/100,000(male 58.56/100,000 and female 34.21/100,000),age-standardized incidence rate by Chinese stand-ard population(ASIRC)was 30.83/100,000,age-standardized incidence rate by World standard population(ASIRW)was 30.61/100,000;The crude mortality was 33.88/100,000(male 45.94/100,000 and female 21.21/100,000),age-standardized mortality rate by Chinese standard population(ASMRC)was 21.70/100,000,age-standardized mortality rate by World standard population(ASMRW)was 21.61/100,000.In 2020,the incidence and mortality of lung cancer in Yunnan province showed an upward trend with the increase of age,and was at a low level before the age of 39,and increased rapidly after the age of 40.It reached its peak in the age groups of 75-79 and 80-84,respectively.The crude incidence of lung cancer in urban and rural areas was 47.21/100,000 and 46.52/100,000,respectively;The crude mortality of lung cancer was 32.66/100,000 and 34.27/100,000,respectively.From 2012 to 2020,the crude incidence of lung cancer in Yunnan province increased with the year(APC=2.94%,95%CI=0.29%-5.67%,P<0.05);The crude incidence of female lung cancer and ASIRW increased with the year(crude incidence rate:APC=6.30%,95%CI=2.52%-10.21%,P<0.05;ASIRW:APC=5.91%,95%CI=1.21%-10.82%,P<0.05).Conclusion In 2020,the incidence and mortality of lung cancer in Yunnan province increase significantly after the age of 40.The overall incidence and mortality of lung cancer in men are higher than those in women,and higher in rural areas than that in urban areas.At the same time,the incidence of lung cancer in women is increasing year by year.Therefore,males 40 years old and over above in rural areas should be identified as key populations for lung cancer prevention and control.Simultaneously,women lung cancer also pay attention to the prevention and control.